Mammogen, a female-led health company, has successfully secured up to $30 million in a Series A financing round. The investment, led by a prominent U.S. public retirement system, marks a significant step in the company's mission to revolutionize women's health. This capital will accelerate the development of its innovative RNA-powered diagnostics for earlier breast cancer detection.
Addressing a Critical Gap in Women's Health
The company aims to address significant limitations in current breast cancer screening, especially for women with dense breast tissue. This demographic, comprising over 38 million women in the U.S., often receives less conclusive results from traditional mammography alone. New federal regulations mandating breast density notification have further highlighted the urgent need for supplemental and more precise diagnostic tools.
Mammogen's lead product, genTRU-breast™, is a blood-based molecular assay designed to meet this need. The platform utilizes proprietary RNA biomarkers to provide a real-time biological signal that can complement standard imaging methods. This non-invasive approach is focused on identifying Stage I breast cancer, enabling intervention at the earliest and most treatable stages.
Strategic Allocation of Capital
The Series A funding is earmarked for several key initiatives to advance the company's mission. A primary focus will be on supporting a pivotal prospective clinical study to further validate the technology and support regulatory activities. The capital will also be used to expand strategic partnerships and scale the company's operational infrastructure for future growth.
As Mammogen moves toward commercialization, it plans to leverage existing CLIA-certified laboratory infrastructure to ensure broad accessibility. The company is actively expanding its relationships within the imaging, laboratory, and broader women's health ecosystems. This strategy is designed to seamlessly integrate its technology into the current standard of care for patients and providers.
A Vision for Predictive Diagnostics
Chief Executive Officer Elizabeth Cormier-May emphasized that the company was founded to provide women with more intelligent diagnostic tools. She stated that the financing accelerates the roadmap for genTRU-breast™, enabling more informed healthcare decisions through earlier disease detection. This vision solidifies Mammogen's position as an emerging leader in women's health diagnostics.
Marty Keiser, Founder of parent company IV BioHoldings, described Mammogen as a category-defining opportunity addressing an underserved area in healthcare. He noted that the investment reflects strong institutional confidence in the company's scientific approach and commercial trajectory. This backing positions Mammogen to lead the next wave of innovation in molecular detection for women's health.
This substantial financing round propels Mammogen into its next phase of growth, reinforcing its potential to transform breast cancer screening. By focusing on a non-invasive, RNA-based solution, the company is poised to improve outcomes for millions of women, particularly those with dense breast tissue. The investment underscores a growing market confidence in precision diagnostics to create a new standard of care in women's health.